Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$16.20 -2.7%	$12.40	$7.08 ▼ $17.18	$335.40M	0.82	82,277 shs	83,668 shs
CHRS Coherus Oncology	$0.80 +0.7%	$0.83	$0.66 ▼ $2.43	$92.86M	0.86	2.68 million shs	679,404 shs
PRTA Prothena	$6.47 +2.4%	$6.40	$4.32 ▼ $25.42	$348.28M	0.01	798,449 shs	636,811 shs
TERN Terns Pharmaceuticals	$4.23 -0.7%	$3.47	$1.87 ▼ $11.40	$369.45M	-0.11	1.48 million shs	263,302 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	0.00%	+3.09%	+27.32%	+98.47%	+9.95%
CHRS Coherus Oncology	0.00%	+7.79%	-3.49%	-2.50%	-39.77%
PRTA Prothena	0.00%	+6.41%	+19.59%	-40.31%	-68.07%
TERN Terns Pharmaceuticals	0.00%	+10.44%	+14.32%	+111.50%	-37.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.7924 of 5 stars	0.5	5.0	0.0	3.3	0.0	0.6
CHRS Coherus Oncology	3.728 of 5 stars	3.3	1.0	4.5	0.6	2.5	0.6
PRTA Prothena	3.0483 of 5 stars	4.2	2.0	0.0	1.1	1.7	1.3
TERN Terns Pharmaceuticals	3.9335 of 5 stars	3.3	1.0	4.1	2.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.00	Sell	$12.00	-25.90% Downside
CHRS Coherus Oncology	2.67	Moderate Buy	$4.68	484.69% Upside
PRTA Prothena	2.33	Hold	$31.50	386.86% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	269.39% Upside

Current Analyst Ratings Breakdown

Latest CHRS, AMRN, PRTA, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$7.00 ➝ $12.00
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00
5/27/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/13/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$228.61M	1.47	N/A	N/A	$23.62 per share	0.69
CHRS Coherus Oncology	$266.96M	0.35	$0.29 per share	2.78	($1.14) per share	-0.70
PRTA Prothena	$135.16M	2.58	N/A	N/A	$9.05 per share	0.71
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$82.18M	-$3.64	N/A	N/A	N/A	-41.07%	-17.21%	-12.16%	7/30/2025 (Estimated)
CHRS Coherus Oncology	$28.51M	-$1.13	N/A	N/A	N/A	-66.30%	N/A	-26.51%	8/6/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)

Latest CHRS, AMRN, PRTA, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.29	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	AMRN Amarin	-$0.60	N/A	N/A	N/A	$45.45 million	N/A
5/12/2025	Q1 2025	CHRS Coherus Oncology	-$0.31	-$0.35	-$0.04	-$0.49	$59.79 million	$7.60 million
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.53	2.55
CHRS Coherus Oncology	N/A	1.22	1.20
PRTA Prothena	N/A	9.00	9.00
TERN Terns Pharmaceuticals	N/A	30.89	30.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
CHRS Coherus Oncology	72.82%
PRTA Prothena	97.08%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	1.96%
CHRS Coherus Oncology	8.08%
PRTA Prothena	9.20%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	20.71 million	20.30 million	Optionable
CHRS Coherus Oncology	330	115.93 million	106.57 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable

CHRS, AMRN, PRTA, and TERN Headlines

Recent News About These Companies

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4 at 3:00 PM | finance.yahoo.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Purchases $39,300.00 in Stock

June 30, 2025 | marketbeat.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Buys 23,314 Shares of Stock

June 25, 2025 | marketbeat.com

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

Population-Level Weight Loss Seen With Primary Care Protocol

June 21, 2025 | medscape.comM

SG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

June 18, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys $19,750.00 in Stock

June 17, 2025 | insidertrades.com

Insider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys 5,000 Shares of Stock

June 16, 2025 | marketbeat.com

Andrew Gengos Buys 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

June 16, 2025 | marketbeat.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 14, 2025 | marketbeat.com

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight

June 13, 2025 | theglobeandmail.com

3 Penny Stocks Wall Street Sees With 243% Upside

June 11, 2025 | 247wallst.com

Bank of America Corp DE Purchases 138,661 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

June 7, 2025 | marketbeat.com

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025 | globenewswire.com

Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential

May 27, 2025 | investing.com

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, AMRN, PRTA, and TERN Company Descriptions

Amarin NASDAQ:AMRN

$16.20 -0.46 (-2.73%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$16.41 +0.22 (+1.35%)

As of 07/3/2025 04:01 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Coherus Oncology NASDAQ:CHRS

$0.80 +0.01 (+0.74%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$0.78 -0.03 (-3.12%)

As of 07/3/2025 04:55 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Prothena NASDAQ:PRTA

$6.47 +0.15 (+2.37%)

Closing price 07/3/2025 03:46 PM Eastern

Extended Trading

$6.41 -0.06 (-0.94%)

As of 07/3/2025 04:52 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Terns Pharmaceuticals NASDAQ:TERN

$4.23 -0.03 (-0.70%)

As of 07/3/2025 02:49 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time